Jun 27, 2025
Abroticinib is a JAK inhibitor approved by the FDA in 2022 for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis who cannot receive other systemic agents, or whose disease is not adequately controlled by other therapies.
The latest articles and insights from your colleagues in your specialty(ies) of choice.
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
Create Post
Twitter/X Preview
Logout